Weill Cornell GI Oncology Program

04/02/2026

In another Targeted Oncology interview, Dr. Rutika Mehta talks about gaps that should be addressed before circulating tumor DNA (ctDNA) testing is more widely integrated into standard of care for patients:

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials.

03/31/2026

March is . Did you know that mismatch repair-deficient has unique traits that change how it responds to treatment? Dr. Manish Shah spoke with two experts on the CancerCast podcast about how immunotherapy and genetic testing for are changing outcomes for people with this form of and who are most at risk for developing it. Listen to the episode: https://bit.ly/4hyecwH

03/30/2026

Hosted by Dr. Manish Shah, Chief of the Soid Tumor Oncology Program Weill Cornell Medicine, the CancerCast podcast offers conversations designed to support, inform, and empower people living with cancer, their loved ones, and caregivers. Each episode features in depth discussions with leading experts who help break down complex advances in cancer diagnosis, treatment, and research. Recent topics explore cutting edge technologies and breakthroughs across many types of cancer. Tune in and subscribe to stay informed about the innovations and insights shaping the future of cancer care.

Listen to the episodes on Apple Podcasts (https://bit.ly/40IugnI), Spotify (https://bit.ly/47r9c94), YouTube (https://bit.ly/4nRMEon), or at weillcornell.org/cancercast.

03/30/2026

From : Dr. Rutika Mehta talked with Oncology Learning Network about reintroducing after previously stopping it for patients with /

Rutika Mehta, MD, discusses whether immunotherapy rechallenge should be considered for patients with esophageal and gastric cancers.

03/26/2026

In this interview with Targeted Oncology, Dr. Rutika Mehta outlines what clinicians should know when deciding to use circulating tumor DNA (ctDNA) or minimal residual disease (MRD) testing to manage patients:

Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans.

03/19/2026

ICYMI: Dr. Rutika Mehta spoke with Targeted Oncology about the role of circulating tumor DNA (ctDNA) to improve early detection of recurrence in .

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

03/12/2026

Dr. Rutika Mehta spoke with Targeted Oncology about a study looking at using circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing in to help inform prognosis, treatment duration, toxicity, and potential treatment breaks:

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

02/26/2026

12/23/2025

Dr. Rutika Mehta moderated a program to discuss results from a phase 3 evaluating a combination treatment regimen recently approved by the U.S. Food and Drug Administration for :

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.

12/11/2025

Watch Dr. Despina Siolas provide insights into the important we’re doing Weill Cornell Medicine to find ways to personalize treatment:

Dr. Despina Siolas, assistant professor of medicine at Weill Cornell Medicine, is working to personalize treatment for pancreatic cancer and develop new therapeutic regimens that save more patient lives.

10/29/2025

WATCH: Dr. Rutika Mehta discusses targeted approaches to biomarker testing for patients with upper gastrointestinal ( ) malignancies:

Rutika Mehta, MD, MPH, discusses targeted approaches to biomarker testing for patients with upper gastrointestinal malignancies.

09/23/2025

Dr. Despina Siolas spoke with Women's Health about potential symptoms that shouldn’t be ignored as part of an article on when to see a doctor for health concerns:

Beyond the expected ones.